{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Pique-Gili M"],"funding":["Alfonso Martín Escudero Foundation","NCATS NIH HHS","University Jaume I Department of Mathematics","Belgian American Educational Foundation Inc","Ramon Areces Foundation","National Institutes of Health","August Pi i Sunyer Institute of Biomedical Research","Cholangiocarcinoma Foundation","University of Barcelona","Spanish Association for the Study of the Liver","Horizon 2020 Framework Programme","Samuel Waxman Cancer Research Foundation","Ministerio de Ciencia e Innovación","National Institute for Health Research (NIHR)","NCI NIH HHS","Catalan Digestology Society","US Department of Defense","Damon Runyon Cancer Research Foundation","Spanish Association Against Cancer Scientific Foundation","NIH HHS","Icahn School of Medicine at Mount Sinai"],"pagination":["101212"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC11550205"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["6(11)"],"pubmed_abstract":["<h4>Background & aims</h4>Transforming growth factor β (TGF-β) plays an oncogenic role in advanced cancer by promoting cell proliferation, metastasis and immunosuppression. <i>PMEPA1</i> (prostate transmembrane protein androgen induced 1) has been shown to promote TGF-β oncogenic effects in other tumour types. Thus, we aimed to explore the role of <i>PMEPA1</i> in hepatocellular carcinoma (HCC).<h4>Methods</h4>We analysed 1,097 tumours from patients with HCC, including discovery (n = 228) and validation (n = 361) cohorts with genomic and clinicopathological data. <i>PMEPA1</i> levels were assessed by qPCR (n = 228), gene expression data (n = 869) and at the single-cell level (n = 54). Genetically engineered mouse models overexpressing <i>MYC+PMEPA1</i> compared to <i>MYC</i> were generated"],"journal":["JHEP reports : innovation in hepatology"],"pubmed_title":["Oncogenic role of PMEPA1 and its association with immune exhaustion and TGF-β activation in HCC."],"pmcid":["PMC11550205"],"funding_grant_id":["R01 CA285580","P30 CA196521","S10 OD030463","S10 OD026880","UL1 TR004419","R01 CA273932"],"pubmed_authors":["Fernandez-Martinez E","Montironi C","Pique-Gili M","Barcena-Varela M","Peix J","Sia D","Pinyol R","Gris-Oliver A","Lindblad KE","Thung SN","Llovet JM","Mauro E","Mesropian A","Ruiz de Galarreta M","Cappuyns S","Lambrechts D","Esteban-Fabro R","Keraite I","Andreu-Oller C","Abril-Fornaguera J","Dekervel J","Martinez-Quetglas I","Torres-Martin M","Lujambio A"],"additional_accession":[]},"is_claimable":false,"name":"Oncogenic role of PMEPA1 and its association with immune exhaustion and TGF-β activation in HCC.","description":"<h4>Background & aims</h4>Transforming growth factor β (TGF-β) plays an oncogenic role in advanced cancer by promoting cell proliferation, metastasis and immunosuppression. <i>PMEPA1</i> (prostate transmembrane protein androgen induced 1) has been shown to promote TGF-β oncogenic effects in other tumour types. Thus, we aimed to explore the role of <i>PMEPA1</i> in hepatocellular carcinoma (HCC).<h4>Methods</h4>We analysed 1,097 tumours from patients with HCC, including discovery (n = 228) and validation (n = 361) cohorts with genomic and clinicopathological data. <i>PMEPA1</i> levels were assessed by qPCR (n = 228), gene expression data (n = 869) and at the single-cell level (n = 54). Genetically engineered mouse models overexpressing <i>MYC+PMEPA1</i> compared to <i>MYC</i> were generated","dates":{"release":"2024-01-01T00:00:00Z","publication":"2024 Nov","modification":"2026-06-02T10:38:37.21Z","creation":"2025-04-04T00:21:55.866Z"},"accession":"S-EPMC11550205","cross_references":{"pubmed":["39524206"],"doi":["10.1016/j.jhepr.2024.101212"]}}